Display options
Cite
Guarnotta V, Vigneri E, Pillitteri G, et al. Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis. Diabetol Metab Syndr. 2018;10:40doi: 10.1186/s13098-018-0341-6.
Guarnotta, V., Vigneri, E., Pillitteri, G., Ciresi, A., Pizzolanti, G., & Giordano, C. (2018). Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis. Diabetology & metabolic syndrome, 1040. https://doi.org/10.1186/s13098-018-0341-6
Guarnotta, Valentina, et al. "Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis." Diabetology & metabolic syndrome vol. 10 (2018): 40. doi: https://doi.org/10.1186/s13098-018-0341-6
Guarnotta V, Vigneri E, Pillitteri G, Ciresi A, Pizzolanti G, Giordano C. Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis. Diabetol Metab Syndr. 2018 May 10;10:40. doi: 10.1186/s13098-018-0341-6. eCollection 2018. PMID: 29760789; PMCID: PMC5944025.
Copy Download .nbib Format: NLM
Share it on

Diabetol Metab Syndr. 2018 May 10;10:40. doi: 10.1186/s13098-018-0341-6. eCollection 2018.

Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis.

Diabetology & metabolic syndrome

Valentina Guarnotta, Enrica Vigneri, Giuseppe Pillitteri, Alessandro Ciresi, Giuseppe Pizzolanti, Carla Giordano

Affiliations

  1. Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Section of Diabetes, Endocrinology and Metabolism, University of Palermo, Italy, Piazza Delle Cliniche 2, 90127 Palermo, Italy.

PMID: 29760789 PMCID: PMC5944025 DOI: 10.1186/s13098-018-0341-6

Abstract

BACKGROUND: Idiopathic type 1 diabetes mellitus (IDM) is characterized by an onset with insulinopenia and ketoacidosis with negative β-cell autoimmunity markers and lack of association with HLA. The aim of the study is to compare the clinical and metabolic parameters, the macro and microvascular complications, the adipose tissue dysfunction and the insulin secretion and sensitivity indexes in patients with IDM and autoimmune type 1 diabetes mellitus (ADM) at clinical onset.

METHODS: Thirty patients with IDM and 30 with ADM, matched for age and gender, were retrospectively analyzed. BMI, waist circumference, lipids, glycemia, HbA1c, insulin requirement, glutamic oxaloacetic and glutamic pyruvic transaminases (GOT and GPT), glucagon stimulated c-peptide (GSC-pep) test levels, M value during hyperinsulinemic euglycemic clamp and Visceral Adiposity Index (VAI) were obtained from our database.

RESULTS: Patients with IDM showed a significantly higher BMI (p 0.012), WC (p 0.07), VAI (p 0.004), LDL-cholesterol (p 0.027), GOT (p 0.005), GPT (p 0.001), M value (p 0.006) and GSC-pep peak (p 0.036), with concomitant lower HDL-cholesterol (p < 0.001), than patients with ADM. In addition, patients with IDM showed a more marked familial history for diabetes (p 0.005) and a higher percentage of hepatic steatosis (p 0.001), visceral obesity (p 0.032) and hypercholesterolemia (p 0.007) compared to patients with ADM.

CONCLUSIONS: Patients with IDM show many metabolic complications at onset, such as visceral obesity, hepatic steatosis and hypercholesterolemia and a higher cardiometabolic risk, than patients with ADM, similarly to patients with type 2 diabetes at onset.

Keywords: Cardiovascular risk factors; Insulin resistance; Insulin secretion; Type 1 diabetes; c-Peptides

References

  1. Endocr Pract. 2017 Aug;23 (8):971-978 - PubMed
  2. Diabetes. 2004 Mar;53(3):645-53 - PubMed
  3. Diabetes Care. 2006 Dec;29(12):2755-7 - PubMed
  4. Diabetes Res Clin Pract. 2015 Jan;107(1):31-6 - PubMed
  5. Eur J Intern Med. 2011 Jun;22(3):266-74 - PubMed
  6. Arterioscler Thromb Vasc Biol. 2004 May;24(5):795-7 - PubMed
  7. Diabetes. 1994 Jun;43(6):741-5 - PubMed
  8. Diabetes. 1996 Mar;45(3):337-41 - PubMed
  9. Diabetes. 2013 Mar;62(3):912-22 - PubMed
  10. Cardiovasc Diabetol. 2010 Dec 14;9:88 - PubMed
  11. Diabetologia. 1999 Mar;42(3):380-1 - PubMed
  12. Autoimmunity. 1999;29(1):65-83 - PubMed
  13. Diabet Med. 1985 Jul;2(4):262-4 - PubMed
  14. Diabetes Care. 2001 Jun;24(6):1014-8 - PubMed
  15. Diabetes. 1995 Jul;44(7):790-5 - PubMed
  16. J Clin Endocrinol Metab. 2005 Aug;90(8):4446-51 - PubMed
  17. Diabetes Metab. 1996 Dec;22(6):397-406 - PubMed
  18. Diabetes Care. 1997 Jul;20(7):1183-97 - PubMed
  19. Diabetes Care. 2004 May;27(5):1108-14 - PubMed
  20. Diabetes Care. 2006 Feb;29(2):329-33 - PubMed
  21. Intern Med. 2000 Jan;39(1):10-4 - PubMed
  22. Diabetes. 2005 Dec;54 Suppl 2:S62-7 - PubMed
  23. J Endocrinol Invest. 2013 Jul-Aug;36(7):537-43 - PubMed
  24. Circulation. 2006 Jun 27;113(25):2943-6 - PubMed
  25. Diabetes Care. 2010 Apr;33(4):920-2 - PubMed
  26. Eur J Clin Invest. 2013 Feb;43(2):183-9 - PubMed
  27. J Obes. 2013;2013:393192 - PubMed
  28. J Clin Endocrinol Metab. 1987 Jul;65(1):30-6 - PubMed
  29. J Diabetes Res. 2015;2015:485132 - PubMed
  30. Diabetes Care. 1996 Jun;19(6):671 - PubMed
  31. PLoS One. 2014 Mar 20;9(3):e91969 - PubMed
  32. Science. 2005 Jan 21;307(5708):426-30 - PubMed
  33. Diabetes. 1995 Apr;44(4):466-70 - PubMed
  34. Diabet Med. 2017 Mar;34(3):426-431 - PubMed
  35. Am J Physiol. 1979 Sep;237(3):E214-23 - PubMed
  36. Diabetes Care. 1998 Aug;21(8):1376-8 - PubMed
  37. Diabetes Care. 2013 Jan;36(1):118-23 - PubMed
  38. Diabet Med. 2001 Jan;18(1):10-6 - PubMed
  39. Pediatrics. 1997 Jul;100(1):84-91 - PubMed
  40. Diabetes Care. 2013 Dec;36(12):4098-103 - PubMed
  41. Trends Endocrinol Metab. 2011 Jul;22(7):259-65 - PubMed

Publication Types